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As a concept, ”information society” first emerged in the
public debate as long ago as the early 1990s. In those
days, information society became a major target in re-
newing economic structures and the public administra-
tion in Finland. That development has been pursued in
the form of several explorative and fact finding projects.
The issue has been included in Prime Minister Paavo
Lipponen’s government policy and programme. In April
1999, the following items were added to the govern-
ment programme: ”Finland will be turned into an infor-
mation society, in which knowledge and skills are an es-
sential part of education and culture, and the principal
factor in production. Her policy on technology shall
place Finland in the vanguard of developed nations. Fin-
land wants to set an example for others in creating a
humane and sustainable information society. That ob-
jective involves developing electronic services, and cul-
tural and other informative content or substance that is
safe and easy to access and use by everyone, whether
the medium be a computer, digital television, or mobile
telecommunication equipment.” 
Building electronic networks to facilitate transactions
between the citizens and the public administration has
progressed relatively rapidly in various public organisa-
tions, departments, facilities and agencies, in keeping
with the ‘Nation in the Forefront’ objective.  We have
hardly earned a gold medal in this matter so far.  There
is still work to be done before the next Olympic Games.
In facilitating electronic transactions, most organisation
and government departments have advanced to the stage
of having their own web pages in the Internet. The ser-
vice they thus provide in the Internet is mainly informa-
tive in nature, enabling information searches. The oppor-
tunity to ask the Webmaster questions is often a part of
this service. Public administration organisations are only
now creating systems for producing actual electronic ser-
vices.  Some pilot projects have already created success-
ful solutions. For instance those pertaining to statistics,
address, and motor vehicle data systems. Commercial in-
terests are clearly speeding up the development of elec-
tronic transaction systems for the citizens.
In terms of the information society objective, a citi-
zen, individual, or organisation shall be able to initiate a
process or matter with a public administration organisa-
tion through electronic media. Information safety is an
important aspect of transactions with the public admin-
istration.  Both the citizen and the public authority must
be certain of the identity of the person initiating a trans-
action or raising a matter. Legislation controlling per-
sonal identification and the production of electronic sig-
natures came into force at the beginning of December
1999. In this regard, the framework exists, but suitable
applications and hardware are not yet commonplace. 
The trend is obvious, and the speed of these develop-
ments is considerable. Information safety also means
that both the citizen and the authority must be able to
trust that the requirements of confidentiality of transac-
tions are met even in electronic transactions between the
parties. A closed network is not a comprehensive solu-
tion between client and authority, at least not in an
open operating environment and with a large number of
citizens as clientele.
The development of electronic transaction systems in
the field of medicines could be described in terms of an
increasing volume and broadening coverage of informa-
tion due to be become accessible in the informative web
pages of National Agency for Medicines. With increas-
ing volume, I am referring to the possibility that our
clientele, partners and interest groups could link their
own web pages to the already extensive body of data
available through our web pages.  As I understand it,
broadening the coverage refers to making additional in-
formation available. The objective is to have the sum-
maries of products characteristics (SPCs) and package
inserts (PILs) of medicines accessible to all citizens on
NAM’s web pages. 
The next, and far greater step in the development of
electronic transactions, will be the adoption of a system,
in which every stage from initiating the action, making
an application, and its processing will all take place via
the Internet. Information safety issues are the foremost
problems still to be solved. The advantages for both the
clients and the authorities are so significant that this ob-
jective is worth striving for.
Juhani Sivula
HEAD OF DEPARTMENT
Department of General Affairs
National Agency for Medicines
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Summary 
Regular use of basic emulsion creams
will moisturise the skin, prevent
chapping of affected patches and re-
lieve itching.  Antihistamines are re-
quired if the rash is itchy.
Peeling off scale 
Keratolytic treatment prepares the
rash for effective treatment during
the course of the disease.  Forcible re-
moval of scales is not recommended
since disease activation is enhanced
by damage to the lesions (Koebner
phenomenon).
The most common keratolytic
treatment consists of 2–10% salicylic
acid in vaseline.  A 2–3% concentra-
tion may be adequate for thin patch-
es on the body and legs and arms,
whereas a concentration of 5–10% is
necessary for thick patches on the
soles or palms, and for the scalp. The
risk of overdose should be kept in
mind when treating children and very
extensive areas affected with psoria-
sis, since about 60% of the salicylic
acid is absorbed from the skin. Sali-
cylic acid/keratolytic therapy should
not immediately precede photothera-
py since it attenuates the effect of UV
light.
Vaseline should not be prescribed
to treat the scalp as it cannot be
washed out of the hair. For peeling
off scales of the scalp, for example, a
5–10% salicylic acid ointment or oil
can be used, rubbing it into hair part-
ings made over the scaling areas of
the scalp and by leaving it overnight.
The hair usually requires to be
washed 2–3 times with a shampoo
following scaling off treatment.
Loose scales are either brushed or
combed out of the hair.
Topical treatment
Tar has been used in the treatment of
psoriasis for over a hundred years
Mild preparations containing coal tar
(Pyroleum lithanthracis) or coal tar
spirit (Spiritus carbonis detergens) are
appropriate in the outpatient care
and treatment of mild psoriasis, but
due to their unpleasant odour and
messy methods of application the use
of more potent preparations is most
practical in hospital.
Popular corticosteroids
Topical corticosteroid therapy is rec-
ommended in the short-term treat-
ment of plaque psoriasis because it
is easy to use and well tolerated.
Absorption is more efficient from a
fatty ointment than from an emul-
sion cream.  General instructions in-
clude the use for 2–4 weeks of corti-
costeroid which has been chosen on
the basis of the location and severity
of the eruption.  Thereafter the
treatment is withdrawn gradually.  
Moderate potent corticosteroid
preparations are used on thin skin
areas, and potent or very potent cor-
ticosteroids are used elsewhere.
The risk of systemic adverse ef-
fects should be kept in mind when
large areas of skin are treated. Topi-
cal adverse effects include atrophy,
striae (streak lines) and telangiec-
tases. Tachyphylaxis or renewed flar-
ing up of skin symptoms (rebound ef-
fect), induced by quick withdrawal of
corticosteroids, may be associated
with a prolonged course of treat-
ment.
Calcipotriol a vitamin D derivative
Calcipotriols efficacy corresponds to
that of corticosteroids of Group III.
The amount of calcipotriol ointment
used in one week should not exceed
100 g. The amount used in one week
by children over the age of 12 should
not exceed 75 g, and 50 g is the max-
imum weekly amount for children
between the age of 6 and 12. At
these dosages calcipotriol will not af-
fect the body’s calcium metabolism.
The results will show typically in 6–8
weeks. Calcipotriol will not cause
thinning of the skin or tachyphylaxis,
but local irritation occurs in 5–25%
of patients. Calcipotriol should not
normally be used on the facial area,
and its use in flexures should be
avoided.
A patch of psoriasis may retain its
redness following calcipotriol thera-
py. A corticosteroid may be used as a
possible adjunct to calcipotriol treat-
ment by using one drug in the morn-
ing and the other in the evening.
This will produce a more complete
remission of patches.
Tazarotene a vitamin A derivative
Tazarotene is a synthetic retinoid, on-
ly less than 5% of which is absorbed
through the skin. In practice, the
most common adverse effect is irrita-
tion of the skin. Tazarotene therapy
is most appropriate for a patient with
a maximum of 10% of skin area, in-
volving the body, legs and arms, af-
fected by plaque psoriasis.  The gel is
applied in the evening, thinly and on-
ly on the areas of rash, avoiding any
healthy skin, flexures and the face.
The symptoms of irritation include
redness of the skin, pruritus, burning
sensations and even pain in the skin.
If the psoriasis is severely in-
flamed, a two-week course of treat-
ment with a very potent corticos-
teroid is recommended, and
tazarotene therapy is continued there-
after.  To improve the effectiveness
Medical treatment of psoriasis
Tutta Uurasmaa
MD
University of Turku
Leena Koulu
MD 
Turku University Central Hospital
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and toleration a potent corticosteroid
may be used on alternate days, with
tazarotene or as adjuvant therapy
once a day.  The typical duration of
tazarotene therapy is 12 weeks. The
drug must not be administered to
women who are planning pregnancy
or are pregnant or breast-feeding.
Tazarotene may be combined with
methotrexate and cyclosporin thera-
py, but not with systemic retinoid
therapy with acitretin.
Disregarded dithranol
The disadvantages of dithranol in-
clude irritation of the skin and stain-
ing. The ”minutes method” is appro-
priate in outpatient care;  the cream
only applied to affected skin areas
for 10–30 minutes once a day, after
which it is washed away.  The use of
an acid detergent will reduce stain-
ing. The eyes, mucous membranes
and the neighbourhood of flexures
must be avoided. Administration of
dithranol is suitable for children and
during pregnancy.  No tolerance is
developed.
The tools of a dermatologist 
include systemic treatment 
Systemic antipsoriatics are considered
for the treatment of rash affecting ex-
tensive skin areas if other treatment
is inadequate or the patient suffers
from treatment exhaustion. Erythro-
dermic generalised pustular and
arthritic psoriasis usually require in-
ternal drugs. Intermittent therapy re-
duces the long-term risks of medica-
tion.
Methotrexate has been used for
treating psoriasis over half a 
century
In the treatment of psoriasis, metho-
trexate is administered once a week.
Patients like methotrexate therapy
because the response is achieved
quickly and they usually notice no
adverse effects. 
Methotrexate is excreted mostly
via the urine, and consequently, even
mild renal insufficiency needs to be
taken into consideration when ad-
ministering the drug.  The risks of
leucopenia and thrombocytopenia
are increased by e.g. sulphas,
NSAIDs, tetracyclines, penicillins,
phenytoin, diphenylhydantoin,
furosemide, corticosteroids, barbitu-
rates and probenicid.  The treatment
is contraindicated in bone-marrow
dyscrasias and in patients with active
or recent gastric or duodenal ulcer.
Folic acid therapy can be given to
prevent nausea and the bone marrow
toxicity of methotrexate.
The biggest risks of long-term ad-
ministration are chronic hepatitis and
cirrhosis.  Liver biopsy (1.5g total
dose intervals) or measurement of the
serum levels of aminoterminal pro-
peptide of type III procollagen are
recommended as a means of moni-
toring.
Acitretin produces excessive 
scaling in psoriasis
Acitretin is exceptionally teratogenic,
and it should not be administered to
a woman of child-bearing age unless
reliable contraception is used during,
and for two years after completion
of, the treatment. Acitretin is used in
the treatment of extensive erythro-
dermic, topical, generalised pustular
psoriasis. Acitretin is contraindicated
in patients with severe hepatic or re-
nal insufficiency.
At the start of acitretin therapy
the affected areas produce more
scales and seem increasingly inflamed
for 6–8 weeks. The after effect of
retinoid therapy is long-lasting, and
the patient may stay symptom-free
for months following completion of
therapy.  Adverse effects include dry-
ness of mucous membranes, loss of
hair and infection of the nail folds.
Adverse effects associated with
long-term use include hepatoxicity,
increased levels of serum triglyceride
and cholesterol, and skeletal changes.
Retinoid therapy which has lasted for
several years may be associated with
skeletal malformation.
Cyclosporin acts as a brake on
immune processes
Cyclosporin is kept specifically for
the treatment of severe psoriasis in
cases where other treatment is inef-
fective or inappropriate. Cyclosporin
therapy should not be introduced in
patients with untreated infections,
immune deficiency or a history of
malignancy.  Induction of cyclosporin
therapy requires careful considera-
tion in patients who have received
large amounts of UV phototherapy,
lest it increases unnecessarily the risk
to the patient of light-induced cancer.
Long-term treatment carries the
risk of nephropathy.  Other drugs
causing renal toxicity should not be
used during treatment.
What is UV phototherapy and
with what treatment can it be
combined?
UV phototherapy  is classified into
types UVA and UVB. The healing ef-
fect of ultraviolet rays on psoriasis is
restricted on the erythematogenic
UVB band, and the treatments (UVB
and SUP) have an anti-inflammatory
and immunosuppressive effect.  In
photochemotherapy, i.e. PUVA thera-
py, the skin is sensitised both inter-
nally and externally with a psoralen-
containing preparation and exposed
to UVA radiation (psoralen + UVA).
UV phototherapy is given to psoriat-
ics under the supervision of a special-
ist.
Outlook
A better understanding of the causes
of psoriasis will make it possible to
develop and improve the direction of
therapies towards the various phases
of the aetiology.  Active research is
focussed on genetics, immunology,
intercellular signals and transcription
factors.  New analogues of vitamin
D3 (tacalcitol and 22-oxacalcitriol,
i.e. liver calcitol) are developed for
topical treatment of psoriasis.  Re-
search among retinoids has focussed
on systemic bexarotene for the treat-
ment of moderate and severe psoria-
sis.  Liarozol is an imidazole deriva-
tive which inhibits the metabolism of
cytochrome P450-dependent retinoic
acid and thereby increases the blood
retinoic acid concentration.  The fo-
cus of research within immunothera-
py is concentrated on e.g. immuno-
suppressive interleukin-10 and hu-
man monoclonal anti-IL8 antibody.
Combinations of treatments are also
being developed to include the sys-
temic treatments of psoriasis avail-
able today, e.g. rapamycin (sirolimus)
combined with cyclosporin therapy
in small doses.  Information obtained
from genetic research may even make
gene therapy of psoriasis possible in
the future.
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Difficult introduction of a new antirheumatic drug
A new drug for the treatment of rheumathoid arthritis,
etanercept (Enbrel) is a TNF-modulator.  It has been
granted marketing authorisation in the EU centralised ap-
proval system, but so far has been prescribed in Finland
for only a small number of patients.  A total of 80.000 pa-
tients world-wide have been treated with etanercept.
In clinical trials the drug was well tolerated, and the most
severe adverse reaction was increased susceptibility to in-
fections.  New features have emerged since the drug has
been introduced on the market.  An abstract recently pub-
lished at a meeting of the American College of Rheuma-
tology discusses four cases which indicate that etanercept
may be associated with exacerbation of multiple sclerosis.
Recent world-wide reports on the use of etanercept in-
clude three cases with associated aplastic anemia and sev-
en cases of pancytopenia;  in five of these cases the patient
died of sepsis.  The drug treatment in these cases had last-
ed between two weeks and five months, and some of the
patients had had either previous or concurrent treatment
with known myelosuppressive drugs such as methotrex-
ate, leflunomide, 6-mercaptopurine, cyclophosphamide or
azathioprine.
It is recommended that patients on Enbrel therapy be ad-
vised to seek medical treatment at once should unexpect-
ed liability to bleed or bruise, or susceptibility to infec-
tions, supervene.
Ventricular arrhytmias associated with antipsychotics
Ventricular arrhythmias associated with the use of various
drugs have recently been discussed widely (in TABU
6/1999, 4/2000), the most recent case being cisapride.
Many neuroleptic drugs, including thioridazine, haloperi-
dol and sertindol have been alleged to prolong the QT in-
terval and cause the ventricular tachycardia known as tor-
sade de pointes (wave-burst arrhythmia).  Consequently,
authorisation for the marketing of sertindol has been can-
celled temporarily.  Among the older neuroleptic drugs,
thioridazine has been the first to undergo closer scrutiny;
this has resulted in the USA last summer, and in Finland
this autumn, in restriction of the indications for thiori-
dazine, which is now prescribed only as a secondary drug
in the treatment of psychosis.
Reassessment of all neuroleptic agents with regard to their
potential for causing arrhythmias has meanwhile begun in
the CPMP Working Party on Pharmacovigilance.
Tendinitis associated with fluoroquinolones may be prolonged
This year the National Agency for Medicines has so far re-
ceived two reports on Achilles tendinitis commencing dur-
ing ofloxacin therapy of usual duration;  the condition has
lasted more than a year in one case, and five months in the
other.  Tendinitis associated with fluoroquinolones is usu-
ally cured relatively quickly, but according to the litera-
ture the condition is known to be prolonged in about
10% of such patients.  Long-term lesions have also been
found in animal models.
Erkki Palva
PROFESSOR, RESEARCH DIRECTOR
Drug Information Centre
National Agency for Medicines
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